SLRN FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages SLRN Investors with Substantial Losses to Contact Firm Before Jan. 16th Deadline in Securities Fraud Lawsuit Stemming from Drug Candidate’s Progress
January 15, 2024 15:04 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023...
SLRN 6-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages SLRN Investors with Substantial Losses to Contact Firm Before Jan. 16th Deadline in Securities Fraud Lawsuit
January 10, 2024 18:49 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023...
Analyst Says Acelyrin (SLRN) Dosing Errors Create “Too Much Uncertainty,” Securities Class Action Pending - Hagens Berman
January 07, 2024 10:50 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
SLRN 12-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages SLRN Investors with Substantial Losses to Contact Firm Before Jan. 16th Deadline in Securities Fraud Lawsuit Stemming from Drug Candidate’s Progress
January 04, 2024 15:01 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4,...
Acelyrin (SLRN) Faces Investor Fraud Lawsuit for Allegedly Lying About Drug Candidate’s Progress-Hagens Berman
January 01, 2024 09:35 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Jan. 01, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Analyst Says Acelyrin (SLRN) Dosing Errors Create “Too Much Uncertainty,” Securities Class Action Pending - Hagens Berman
December 29, 2023 13:50 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Analyst Says Acelyrin (SLRN) Dosing Errors Create “Too Much Uncertainty,” Securities Class Action Pending - Hagens Berman
December 22, 2023 14:22 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Investors Say Acelyrin (SLRN) Lied About Drug Candidate’s Progress-Hagens Berman
December 18, 2023 16:14 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023 –...
Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline
December 17, 2023 08:01 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox reminds Acelyrin investors of a class action lawsuit and upcoming deadline.
Acelyrin (SLRN) Discloses CRO Errors in Izokibep Program in Wake of Investor Class Action -Hagens Berman
December 15, 2023 16:34 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023...